Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone versus metformin for nonalcoholic fatty liver disease
IRCT20211014052767N1Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Metformin with Pioglitazone (2 arms). Primary endpoints: Fasting blood sugar, Liver enzyme levels and 2 more. Started Nov 2021; status: completed.
02
Drugs
pioglitazonemetformin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20211014052767N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211014052767N1.